SG11201810854SA - Aliphatic prolinamide derivatives - Google Patents
Aliphatic prolinamide derivativesInfo
- Publication number
- SG11201810854SA SG11201810854SA SG11201810854SA SG11201810854SA SG11201810854SA SG 11201810854S A SG11201810854S A SG 11201810854SA SG 11201810854S A SG11201810854S A SG 11201810854SA SG 11201810854S A SG11201810854S A SG 11201810854SA SG 11201810854S A SG11201810854S A SG 11201810854SA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- amd
- applicant
- retinopathy
- pct
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
- C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Abstract
Title: ALIPHATIC PROLINAMIDE DERIVATIVES Ric R3a R 3 b 0 R 1 I (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 28 December 2017 (28.12.2017) WIPO I PCT omit VIII Hot o Homomomim Holm° lII ois (10) International Publication Number WO 2017/222917 Al (51) International Patent Classification: CO7D 207/08 (2006.01) A61K 31/40 (2006.01) CO7D 207/09 (2006.01) A61K 31/454 (2006.01) C07D 401/04 (2006.01) (21) International Application Number: PCT/US2017/037773 (22) International Filing Date: 15 June 2017 (15.06.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/352,965 21 June 2016 (21.06.2016) US (71) Applicant: INCEPTION 4, INC. [US/US]; 5871 Oberlin Drive, Suite 100, San Diego, CA 92121 (US). (72) Inventors: CHEN, Austin, Chih-Yu; 1142 Festival Road, San Marcos, CA 92078 (US). GOMEZ, Robert; 3344 Mt. Seymour Parkway, North Vancouver, British Colum- bia, V7H 1G3 (CA). OBALLA, Renata, Marcella; 1973 Custer Court, Coquitlam, British Columbia, V3J 6R2 (CA). POWELL, David, Andrew; 1781 Napier Street, Vancou- ver, British Columbia, V5L 2N1 (CA). ROPPE, Jeffrey, Roger; 45004 Oakford Court, Temecula, CA 92592 (US). SEIDERS, Thomas, Jon; 5257 Soledad Mountain Road, San Diego, CA 92109 (US). SHENG, Tao; 631 Elbert Av- enue, Coquitlam, British Columbia, V3J 2L1 (CA). (74) Agent: MALLON, Joseph, J.; Knobbe Martens Olson & Bear LLP, 2040 Main Street, Fourteenth Floor, Irvine, CA 92614 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). W O 20 17 / 2229 17 Al (57) : This invention is directed to novel aliphatic prolinamide derivatives of Formula I, and pharmaceutically acceptable salts, sol- vates, solvates of the salt and prodrugs thereof, useful in the preven- tion (e.g., delaying the onset of or reducing the risk of developing) and treatment (e.g., controlling, alleviating, or slowing the progression of) of age-related macular degeneration (AMD) and related diseases of the eye. These diseases include dry-AMD, wet-AMD, geographic atrophy, diabetic retinopathy, retinopathy of prematurity, polypoidal choroidal vasculopathy, and degeneration of retinal or photoreceptor cells. The invention disclosed herein is further directed to methods of prevention, slowing the progress of, and treatment of dry-AMD, wet-AMD, and geographic atrophy, diabetic retinopathy, retinopathy of prematurity, polypoidal choroidal vasculopathy, and degeneration of retinal or pho- toreceptor cells, comprising: administration of a therapeutically effec- tive amount of compound of the invention. The compounds of the in- vention are inhibitors of HTRAl. Thus, the compounds of the invention are useful in the prevention and treatment of a wide range of diseases mediated (in whole or in part) by HTRAl. The compounds of the in- vention are also useful for inhibiting HTRA1 protease activity in an eye or locus of an arthritis or related condition. [Continued on next page] WO 2017/222917 Al IMEDIMOMMIONOIDEMEEHOEMIHOEHME#011# Declarations under Rule 4.17: as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(H)) as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) Published: — with international search report (Art. 21(3))
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662352965P | 2016-06-21 | 2016-06-21 | |
PCT/US2017/037773 WO2017222917A1 (en) | 2016-06-21 | 2017-06-15 | Aliphatic prolinamide derivatives |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201810854SA true SG11201810854SA (en) | 2019-01-30 |
Family
ID=60783556
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201810854SA SG11201810854SA (en) | 2016-06-21 | 2017-06-15 | Aliphatic prolinamide derivatives |
Country Status (17)
Country | Link |
---|---|
US (1) | US10730832B2 (en) |
EP (1) | EP3472130B1 (en) |
JP (1) | JP7076438B2 (en) |
KR (1) | KR102512201B1 (en) |
CN (1) | CN109563033B (en) |
AU (1) | AU2017282653B2 (en) |
BR (1) | BR112018076766A2 (en) |
CA (1) | CA3026505A1 (en) |
EA (1) | EA201990070A1 (en) |
ES (1) | ES2917194T3 (en) |
IL (1) | IL263282B (en) |
MX (1) | MX2018016102A (en) |
PH (1) | PH12018502697A1 (en) |
SG (1) | SG11201810854SA (en) |
UA (1) | UA123836C2 (en) |
WO (1) | WO2017222917A1 (en) |
ZA (1) | ZA201808054B (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10526315B2 (en) | 2016-06-21 | 2020-01-07 | Orion Ophthalmology LLC | Carbocyclic prolinamide derivatives |
WO2017222915A1 (en) | 2016-06-21 | 2017-12-28 | Inception 4, Inc. | Heterocyclic prolinamide derivatives |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5948886A (en) * | 1996-11-20 | 1999-09-07 | Hoechst Marion Roussel, Inc. | Acylated enol derivatives of α-ketoesters and α-ketoamides |
BR9712544B1 (en) | 1996-10-18 | 2013-10-22 | SERINE PROTEASE INHIBITORS, PHARMACEUTICAL COMPOSITION UNDERSTANDING THE SAME AND ITS USES | |
AU2001276988B2 (en) * | 2000-07-21 | 2007-01-25 | Dendreon Corporation | Peptides as NS3-serine protease inhibitors of hepatitis C virus |
US7244721B2 (en) | 2000-07-21 | 2007-07-17 | Schering Corporation | Peptides as NS3-serine protease inhibitors of hepatitis C virus |
SV2003000617A (en) * | 2000-08-31 | 2003-01-13 | Lilly Co Eli | INHIBITORS OF PROTEASA PEPTIDOMIMETICA REF. X-14912M |
CN102267924A (en) | 2003-01-08 | 2011-12-07 | 诺华疫苗和诊断公司 | Antibacterial agents |
US7028988B2 (en) | 2003-10-14 | 2006-04-18 | Pgs Americas, Inc. | Cable handling system |
NZ549223A (en) * | 2004-02-27 | 2010-10-29 | Schering Corp | Sulfur compounds as inhibitors of hepatitis C virus NS3 serine protease |
US20060275366A1 (en) | 2005-06-02 | 2006-12-07 | Schering Corporation | Controlled-release formulation |
AR055395A1 (en) * | 2005-08-26 | 2007-08-22 | Vertex Pharma | INHIBITING COMPOUNDS OF THE ACTIVITY OF SERINA PROTEASA NS3-NS4A OF HEPATITIS C VIRUS |
US7964624B1 (en) | 2005-08-26 | 2011-06-21 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases |
EP2029153A2 (en) | 2006-01-27 | 2009-03-04 | Phenomix Corporation | Hepatitis c serine protease inhibitors and uses therefor |
EP1881002A1 (en) | 2006-07-20 | 2008-01-23 | Tibotec Pharmaceuticals Ltd. | HCV NS-3 serine protease inhibitors |
EP2495249A1 (en) | 2007-02-26 | 2012-09-05 | Achillion Pharmaceuticals, Inc. | Tertiary amine substituted peptides useful as inhibitors of HCV replication |
CA2681624A1 (en) | 2007-03-23 | 2009-01-15 | Schering Corporation | P1-nonepimerizable ketoamide inhibitors of hcv ns3 protease |
AR069310A1 (en) | 2007-11-13 | 2010-01-13 | Protez Pharmaceuticals Inc | BETA-LACTAMASA INHIBITORS |
US20120095211A1 (en) | 2010-09-22 | 2012-04-19 | Intermune, Inc. | Substituted proline inhibitors of hepatitis c virus replication |
WO2012078540A1 (en) | 2010-12-08 | 2012-06-14 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Modulating immune cell activity using cytokine-induced src homology 2 and/or high temperature requirement a-1 |
WO2013053372A1 (en) | 2011-10-13 | 2013-04-18 | Therabor Pharmaceuticals | Boronic acid inhibitors of beta-lactamases |
WO2016100555A1 (en) | 2014-12-18 | 2016-06-23 | Inception 4, Inc. | Boronic acid derivatives and uses thereof |
AR103742A1 (en) | 2015-02-25 | 2017-05-31 | Hoffmann La Roche | DERIVATIVES OF TRIFLUOROMETILPROPANAMIDA |
EP3294718B1 (en) | 2015-05-11 | 2020-04-29 | H. Hoffnabb-La Roche Ag | New difluoroketamide derivatives |
US10526315B2 (en) * | 2016-06-21 | 2020-01-07 | Orion Ophthalmology LLC | Carbocyclic prolinamide derivatives |
-
2017
- 2017-06-15 MX MX2018016102A patent/MX2018016102A/en unknown
- 2017-06-15 KR KR1020197001754A patent/KR102512201B1/en active IP Right Grant
- 2017-06-15 UA UAA201900589A patent/UA123836C2/en unknown
- 2017-06-15 SG SG11201810854SA patent/SG11201810854SA/en unknown
- 2017-06-15 WO PCT/US2017/037773 patent/WO2017222917A1/en unknown
- 2017-06-15 EP EP17815963.8A patent/EP3472130B1/en active Active
- 2017-06-15 EA EA201990070A patent/EA201990070A1/en unknown
- 2017-06-15 BR BR112018076766-2A patent/BR112018076766A2/en unknown
- 2017-06-15 US US16/312,259 patent/US10730832B2/en active Active
- 2017-06-15 ES ES17815963T patent/ES2917194T3/en active Active
- 2017-06-15 CA CA3026505A patent/CA3026505A1/en active Pending
- 2017-06-15 AU AU2017282653A patent/AU2017282653B2/en active Active
- 2017-06-15 CN CN201780038209.9A patent/CN109563033B/en active Active
- 2017-06-15 JP JP2019519966A patent/JP7076438B2/en active Active
-
2018
- 2018-11-26 IL IL263282A patent/IL263282B/en active IP Right Grant
- 2018-11-28 ZA ZA2018/08054A patent/ZA201808054B/en unknown
- 2018-12-19 PH PH12018502697A patent/PH12018502697A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
IL263282B (en) | 2021-04-29 |
EP3472130A4 (en) | 2019-12-11 |
EP3472130B1 (en) | 2022-02-16 |
JP7076438B2 (en) | 2022-05-27 |
KR20190011321A (en) | 2019-02-01 |
WO2017222917A1 (en) | 2017-12-28 |
UA123836C2 (en) | 2021-06-09 |
CN109563033B (en) | 2023-04-04 |
ZA201808054B (en) | 2023-10-25 |
AU2017282653A1 (en) | 2019-01-17 |
JP2019525952A (en) | 2019-09-12 |
US20190330146A1 (en) | 2019-10-31 |
KR102512201B1 (en) | 2023-03-20 |
CN109563033A (en) | 2019-04-02 |
EA201990070A1 (en) | 2019-06-28 |
MX2018016102A (en) | 2019-08-29 |
IL263282A (en) | 2018-12-31 |
ES2917194T3 (en) | 2022-07-07 |
BR112018076766A2 (en) | 2019-04-02 |
US10730832B2 (en) | 2020-08-04 |
AU2017282653B2 (en) | 2021-08-12 |
PH12018502697A1 (en) | 2019-10-28 |
CA3026505A1 (en) | 2017-12-28 |
EP3472130A1 (en) | 2019-04-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201908330PA (en) | Farnesoid x receptor agonists and uses thereof | |
SG11201806863WA (en) | Tetracyclic pyridone compounds as antivirals | |
SG11201909955XA (en) | Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies | |
SG11201808003RA (en) | Bromodomain inhibitors | |
SG11201908740VA (en) | Sustained release delivery systems comprising traceless linkers | |
SG11201809082WA (en) | Nlrp3 modulators | |
SG11201908598PA (en) | Compounds useful in the treatment or prevention of a prmt5-mediated disorder | |
SG11201811564QA (en) | Methods of treating ovarian cancer | |
SG11201908179UA (en) | Aryl cyclopropyl-amino-isoquinolinyl amide compounds | |
SG11201909245PA (en) | Methods and compositions for treating aging-associated impairments using ccr3-inhibitors | |
SG11201900163PA (en) | Macrocycle kinase inhibitors | |
SG11201811230RA (en) | Compositions and methods for reducing ocular neovascularization | |
SG11201908517XA (en) | Pyrimidinyl-pyridyloxy-naphthyl compounds and methods of treating ire1-related diseases and disorders | |
SG11201808237UA (en) | Substituted indole compound derivatives as dengue viral replication inhibitors | |
SG11201408133TA (en) | Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases | |
SG11201811559WA (en) | Cancer treatment combinations | |
SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
SG11201900558RA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
SG11201909680UA (en) | Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds | |
SG11201907356SA (en) | Piperidine-substituted mnk inhibitors and methods related thereto | |
SG11201408232RA (en) | 1,2,4-triazine-6-carboxamide kinase inhibitors | |
SG11201903312VA (en) | Sulfoxyalkyl organonitro and related compounds and pharmaceutical compositions for use in medicine | |
SG11201408240TA (en) | Treatment of motor and movement disorder side effects associated with parkinson's disease treatments | |
SG11201804885TA (en) | Monomaleimide-functionalized platinum compounds for cancer therapy | |
SG11201407575PA (en) | 5-amino[1,4]thiazines as bace 1 inhibitors |